NCT05783180View on ClinicalTrials.gov

LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

November 30, 2024

Conditions
COVID-19
Interventions
DRUG

Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™

Sesderma LACTYFERRIN™ Forte (64mg/20ml, TID) and Sesderma ZINC Defense™ (20mg/20ml QD)

DRUG

Placebo

Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ (Placebo)

Trial Locations (1)

33155

Keralty Hospital Miami, Miami

Sponsors

Collaborators (1)

MGM Technology Corp
All Listed Sponsors
collaborator

Sesderma S.L.

UNKNOWN

collaborator

Westchester General Hospital Inc. DBA Keralty Hospital Miami

UNKNOWN

collaborator

MGM Technology Corp

UNKNOWN

lead

Jose David Suarez, MD

OTHER

NCT05783180 - LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19 | Biotech Hunter | Biotech Hunter